EVALUATING THE ASSOCIATION BETWEEN APOLIPOPROTEIN A5 SINGLE NUCLEOTIDE POLYMORPHISMS (APOA5 SNPS) AND HYPERTRIGLYCERIDEMIA

M ASLAM; B FAROOQ; FA MALIK; M AJMAL; AR HAMMAD

doi:10.54112/bcsrj.v2023i1.280

Authors

M ASLAM Department of Biochemistry, Govt. College University Faisalabad, Pakistan
B FAROOQ Department of Biochemistry, Nishtar Medical University Multan, Pakistan
FA MALIK Department of Biochemistry, DG Khan Medical College DG Khan, Pakistan
M AJMAL Department of Biochemistry, Nishtar Medical University Multan, Pakistan
AR HAMMAD Department of Physiology, Abwa Medical College Faisalabad, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.280

Keywords:

Fibrate therapy, Single Nucleotide Polymorphism,, Hypertriglyceridemia

Abstract

The retrospective study was conducted at the Faisalabad Institute of Cardiology from January 2022 to January 2023 to evaluate the association between apolipoprotein A5 single nucleotide polymorphisms (APOA5 SNPS) and hypertriglyceridemia in the Pakistani population and assess the efficacy of fibrate therapy in hypertriglyceridemic patients. Blood samples of patients were collected for DNA extraction by the standard inorganic method. Extracted DNA was analyzed biochemically and genetically following the selection and genotyping of the APOA5 gene to know SNP variants with risk alleles. We analyzed lipid profiles, including TG (triglyceride), HDL (high-density lipoprotein), and LDL (low-density lipoprotein) levels of hypertriglyceridemic patients, then compared them to normal and fibrate-treated individuals. We compared APOA5 (rs662799) SNP (single nucleotide polymorphism) among 50 hypertriglyceridemic, 50 healthy controls, and among the same 50 hypertriglyceridemic patients who were given fibrate. Results showed that fibrate decreased TG level and LDL by about 30-45% and 20-25%, respectively; increased high-density lipoprotein by 10-15% and total cholesterol decreased by 6-8% in Pakistani. Hypertriglyceridemia risk was significantly increased by a minor allele of APOA5 rs662799 polymorphism. Minor allele carriers of rs662799 had an odd ratio of (95% CI) 1.5 (1.03-2.18) (P = 0.032). Risk allele frequency differed among hypertriglyceridemic patients, healthy controls, and fibrate-treated hypertriglyceridemic individuals. We analyzed that 87.5% of healthy controls exhibited no risk allele, while 78% did not show this risk allele among hypertriglyceridemic patients. It was concluded that APOA5 rs662799 polymorphism is a genetic determinant of hypertriglyceridemia. Fibrate caused a reduction in TG and LDL and caused an elevation of HDL-C among hypertriglyceridemic patients.

Downloads

Download data is not yet available.

References

Chen, Y. Q., Pottanat, T. G., Zhen, E. Y., Siegel, R. W., Ehsani, M., Qian, Y.-W., and Konrad, R. J. (2021). ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition. Journal of Lipid Research 62.

Chuluun-Erdene, A., Sengeragchaa, O., Altangerel, T.-A., Sanjmyatav, P., Dagdan, B., Battulga, S., Enkhbat, L., Byambasuren, N., Malchinkhuu, M., and Janlav, M. (2020). Association of Candidate Gene Polymorphism with Metabolic Syndrome among Mongolian Subjects: A Case-Control Study. Medical Sciences 8, 38.

Dairawan, M., and Shetty, P. J. (2020). The evolution of DNA extraction methods. Am. J. Biomed. Sci. Res 8, 39-45.

de Luis, D. A., Izaola, O., Primo, D., and Aller, R. (2021). APOA5 variant rs662799, role in cardiovascular traits and serum adipokine levels in Caucasian obese subjects. Annals of Nutrition and Metabolism 77, 299-306.

Hubáček, J. A., Šedová, L., Olišarová, V., Adámková, V., and Tóthová, V. (2020). Different prevalence of T2DM risk alleles in Roma population in comparison with the majority Czech population. Molecular Genetics & Genomic Medicine 8, e1361.

Kim, H.-K., Anwar, M. A., and Choi, S. (2019). Association of BUD13-ZNF259-APOA5-APOA1-SIK3 cluster polymorphism in 11q23. 3 and structure of APOA5 with increased plasma triglyceride levels in a Korean population. Scientific Reports 9, 8296.

Mirabedini, S., Musavi, H., Makhlough, A., Hashemi-Sooteh, M.-B., and Zargari, M. (2023). Association of S19W polymorphism in APOA5 gene and serum lipid levels in patients with type 2 diabetic nephropathy. Hormone Molecular Biology and Clinical Investigation.

Orringer, C. E., Jacobson, T. A., and Maki, K. C. (2019). National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. Journal of clinical lipidology 13, 860-872.

Park, S., and Kang, S. (2020). Alcohol, carbohydrate, and calcium intakes and smoking interactions with APOA5 rs662799 and rs2266788 were associated with elevated plasma triglyceride concentrations in a cross-sectional study of Korean adults. Journal of the Academy of Nutrition and Dietetics 120, 1318-1329. e1.

Ruiz-García, A., Arranz-Martínez, E., López-Uriarte, B., Rivera-Teijido, M., Palacios-Martínez, D., Dávila-Blázquez, G. M., Rosillo-González, A., Delgado, J. A. G.-P., Marino-Suárez, J. E., and Revilla-Pascual, E. (2020). Prevalence of hypertriglyceridemia in adults and related cardiometabolic factors. SIMETAP-HTG study. Clínica e Investigación en Arteriosclerosis (English Edition) 32, 242-255.

Shahid, S. U., Shabana, N., Cooper, J. A., Rehman, A., and Humphries, S. E. (2017). Common variants in the genes of triglyceride and HDL-C metabolism lack association with coronary artery disease in the Pakistani subjects. Lipids in Health and Disease 16, 1-7.

Vrablik, M., Hubacek, J., Dlouha, D., Satny, M., Adamkova, V., and Ceska, R. (2019). Strong association between APOA5 gene polymorphisms and hypertriglyceridaemic episodes. Folia Biologica 65, 188-194.

Xie, T., Stathopoulou, M. G., De Andrés, F., Siest, G., Murray, H., Martin, M., Cobaleda, J., Delgado, A., Lamont, J., and Peñas-LIedó, E. (2017). VEGF-related polymorphisms identified by GWAS and risk for major depression. Translational psychiatry 7, e1055-e1055.

Yu, X.-d., Huang, H., Jiao, Y., Li, J., Fan, X., Zhang, D., and Wang, F.-s. (2023). Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who are treated with combination antiretroviral therapy: a retrospective cohort study. Lipids in Health and Disease 22, 1-10.